Vetoquinol SA (LON:0O1O)

Market Cap	919.66M +32.3%
Revenue (ttm)	456.36M -0.9%
Net Income	51.39M +27.2%
EPS	4.37 +27.9%
Shares Out	n/a
PE Ratio	17.89
Forward PE	17.28
Dividend	0.75 (0.86%)
Ex-Dividend Date	Jun 4, 2025

Volume	1
Average Volume	170
Open	87.40
Previous Close	85.70
Day's Range	87.40 - 88.80
52-Week Range	69.20 - 88.80
Beta	1.02
RSI	64.36
Earnings Date	Mar 27, 2026

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1933
• Employees: 2,497
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0O1O

Financial Performance

In 2024, Vetoquinol's revenue was 539.20 million, an increase of 1.88% compared to the previous year's 529.27 million. Earnings were 58.69 million, an increase of 5.62%.

Financial numbers in EUR